US market expands for Glycosal diabetes test
This article was originally published in Clinica
Executive Summary
Provalis has gained the green light to expand the US market for its Glycosal diabetes test after receiving FDA clearance to sell the test for prescription home use. The US has also granted the product CLIA (Clinical Laboratory Improvement Amendments) waiver status, a regulation designated to diagnostic tests that have been proven to be sufficiently simple and accurate to use, such that erroneous results in the hands of a non-medical user are extremely unlikely.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.